{"id":62144,"date":"2025-11-05T07:02:47","date_gmt":"2025-11-05T06:02:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/"},"modified":"2025-11-05T07:02:47","modified_gmt":"2025-11-05T06:02:47","slug":"galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/","title":{"rendered":"Galderma Receives U.S. FDA Approval for Restylane\u00ae Lyft\u2122 for the Enhancement of the Chin Profile"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nThis approval is based on results showing the safety and effectiveness of Restylane Lyft in enhancing the chin profile, with high patient satisfaction and long-lasting results<sup>1,2<\/sup>\n<\/li>\n<li>\nRestylane Lyft is the only hyaluronic acid (HA) injectable approved to treat the midface, facial folds and wrinkles, back of hands and the chin, with consistent results observed across diverse patient types<sup>1,2<\/sup>\n<\/li>\n<li>\nGalderma\u2019s Restylane portfolio, including Restylane Lyft, is supported by decades of clinical evidence and real patient experiences with over 77 million treatments delivered worldwide<sup>3,4<\/sup>\n<\/li>\n<\/ul>\n<p>ZUG, Switzerland&#8211;(BUSINESS WIRE)&#8211;Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocaine<i> <\/i>for augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.<sup>2<\/sup> Restylane Lyft is a versatile HA injectable with over 20 years of worldwide safety data, which is also approved to treat the midface, facial folds and wrinkles (such as nasolabial folds) and back of hands.<sup>2,3,4<\/sup>\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20251104411888\/en\/2632627\/5\/GALDERMA_LOGO_BLACK_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251104411888\/en\/2632627\/22\/GALDERMA_LOGO_BLACK_RGB.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251104411888\/en\/2632627\/5\/GALDERMA_LOGO_BLACK_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251104411888\/en\/2632627\/21\/GALDERMA_LOGO_BLACK_RGB.jpg\"><\/a><\/p>\n<p>\nThe Restylane portfolio offers a versatile range of HA injectables, from soft and flexible to firm gel formulations, empowering practitioners to deliver personalized aesthetic outcomes.<sup>5-8<\/sup> Restylane Lyft, developed with NASHA<sup>\u00ae<\/sup> technology, has a firmer gel with minimal modification, closely resembling the skin\u2019s natural HA.<sup>9,10<\/sup> With its high G-prime (a measure of firmness), Restylane Lyft is specifically designed to provide structure and support, enabling it to enhance the chin for a balanced profile.<sup>2,5,11<\/sup>\n<\/p>\n<table cellspacing=\"0\" class=\"bwblockalignl bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwrowaltcolor0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u201cThis approval reinforces our commitment to advancing our Injectable Aesthetics portfolio \u2013 the broadest on the market \u2013 to meet the diverse needs of patients. By expanding how innovations like Restylane Lyft can be used, we aim to empower aesthetic practitioners to achieve their patients\u2019 unique aesthetic goals with enhanced flexibility and precision.\u201d\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>BILL ANDRIOPOULOS, PHD<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>VICE PRESIDENT OF MEDICAL AFFAIRS<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>GALDERMA U.S.<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nThe approval is based on results from a pivotal clinical trial, confirming the clinical performance and safety of Restylane Lyft for chin enhancement.<sup>1,2<\/sup> The primary endpoint of the study was met, demonstrating its safety and effectiveness in improving chin projection three months after initial injection, with improvement sustained in the majority of patients through 12 months.<sup>1<\/sup> Additional results showed:<sup>1<\/sup>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nGlobal aesthetic improvement, as assessed by both patients and investigators, remained consistently high throughout the study. At Month 3, 99.1% of investigators and 94.5% of subjects reported visible improvement. These results were maintained at Month 12, with 95.4% of investigators and 89.0% of patients continuing to report positive outcomes\n<\/li>\n<li>\nAt the end of the study (Month 12), a high proportion of patients agreed or strongly agreed that Restylane Lyft delivered natural-looking chin projection, improved the appearance of the lower face, and provided a smooth transition from chin to jawline, with satisfaction rates up to 86.3%\n<\/li>\n<li>\nRestylane Lyft was well tolerated, with no unexpected or serious adverse events related to the product reported during the study, reinforcing its favorable safety profile\n<\/li>\n<\/ul>\n<table cellspacing=\"0\" class=\"bwblockalignl bwtablemarginb\">\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwrowaltcolor0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u201cThe chin plays a vital role in overall facial harmony. Restylane Lyft offers a safe and effective way to enhance this area, helping to bring balance and definition to the face. It\u2019s already a trusted product in my clinic, supported by my own experience and over two decades of global safety data, so I\u2019m pleased to now be able to also offer patients its benefits in the chin.\u201d\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>ALIA S. BROWN, M.D. FAAD<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>ATLANTA BIOMEDICAL CLINICAL RESEARCH AND GEORGIA DERMATOLOGY PARTNERS<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>COSMETIC DERMATOLOGIST<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nRegulatory applications for Restylane Lyft for use on the chin will continue to be submitted and assessed by additional authorities globally. Galderma is working to bring this expanded indication to as many countries as possible.\n<\/p>\n<p>\n<b>IMPORTANT SAFETY INFORMATION<\/b>\n<\/p>\n<p>\n<i>Restylane Lyft with Lidocaine <\/i>is indicated for deep implantation into the facial tissue for the correction of moderate-to-severe facial wrinkles and folds, such as nasolabial folds, for cheek augmentation and for the correction of age-related midface contour deficiencies in patients over the age of 21. <i>Restylane Lyft with Lidocaine<\/i> is also indicated for injection into the dorsal hand to correct volume loss in patients over the age of 21. <i>Restylane Lyft with Lidocaine<\/i> is also indicated for injection into the mid-to-deep dermis (subcutaneous and\/or supraperiosteal) for augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.\n<\/p>\n<p>\n<i>Restylane Lyft with Lidocaine <\/i>contains traces of gram-positive bacterial protein and is contraindicated for patients with allergies to such material or for patients with severe allergies that have required in-hospital treatment. This product should not be used by people with bleeding disorders, with hypersensitivity to amide-type local anesthetics, such as lidocaine, or by women who are pregnant or breastfeeding.\n<\/p>\n<p>\nThe most common side effects reported in the clinical study to support approval of augmentation of the chin region included bruising, nodules, exfoliation, hemorrhage, edema, papules and redness. Patients also reported pain, tenderness, swelling, itching, and lumps\/bumps.\n<\/p>\n<p>\nDelayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers, and cases have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own. Serious but rare side effects include delayed onset infections, recurrence of herpetic eruptions, superficial necrosis, and scarring at the injection site. Do not implant into blood vessels. Use with caution in patients recently treated with anticoagulant or platelet inhibitors to avoid bleeding and bruising.\n<\/p>\n<p>\n<i>Restylane Lyft with Lidocaine<\/i> is only available through a licensed practitioner. Complete Instructions for Use are available <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.galderma.com%2Fsites%2Fdefault%2Ffiles%2F2025-11%2FRestylane_Lyft_IFU.pdf&amp;esheet=54352291&amp;newsitemid=20251104411888&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=e650592ce2a6d4a81ef191ced2986c11\" rel=\"nofollow\" shape=\"rect\">here<\/a>.\n<\/p>\n<p>\n<b>About the Restylane portfolio<\/b>\n<\/p>\n<p>\nRestylane hyaluronic acid (HA) injectables are designed differently to go beyond volumizing for natural-looking results.<sup>1,12-14<\/sup> Our HA is exceptionally pure and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.<sup>9,10,15<\/sup> Restylane\u2019s unique technologies, NASHA HD<sup>\u2122<\/sup>, NASHA and OBT<sup>\u2122<\/sup>\/XpresHAn<sup>\u2122<\/sup> are meaningfully designed to mimic the diverse range of facial structures and skin layers.<sup>12-14<\/sup> With the highest G\u2019 and highest flexibility, Restylane can provide structural support, natural expressions and a healthy glow.<sup>7,13,15-18<\/sup> Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural looking results.<sup>12,19,20<\/sup>\n<\/p>\n<p>\n<b>About Galderma<\/b>\n<\/p>\n<p>\nGalderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body\u2019s largest organ \u2013 the skin \u2013 meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.galderma.com&amp;esheet=54352291&amp;newsitemid=20251104411888&amp;lan=en-US&amp;anchor=www.galderma.com&amp;index=2&amp;md5=e2768cb61e5a1de34309cc823d83ac88\" rel=\"nofollow\" shape=\"rect\">www.galderma.com<\/a>.\n<\/p>\n<p>\n<b>References<\/b>\n<\/p>\n<ol class=\"bwlistdecimal\">\n<li>\nGalderma. Data on file. MA-60800. 43USCH2208 R Lyft Chin US Clinical Study Report.\n<\/li>\n<li>\nRestylane<sup>\u00ae<\/sup> Lyft. Instructions for Use. Available <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.galderma.com%2Fsites%2Fdefault%2Ffiles%2F2025-11%2FRestylane_Lyft_IFU.pdf&amp;esheet=54352291&amp;newsitemid=20251104411888&amp;lan=en-US&amp;anchor=online&amp;index=3&amp;md5=13d8ae7d6badb96834b59093ca294dee\" rel=\"nofollow\" shape=\"rect\">online<\/a>. Galderma Laboratories, L.P., 2025.\n<\/li>\n<li>\nGalderma. Data on file. MA-57232 [Updated]. 77 Million treated.\n<\/li>\n<li>\nGalderma. Data on file. MA-55607. Restylane<sup>\u00ae <\/sup>27 years data publications analysis.\n<\/li>\n<li>\nGalderma Data on file. MA-56724. X-strain and G\u2019 including Shaype.\n<\/li>\n<li>\nNikolis A, Humphrey S, Rivers JK, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. <i>J Drugs Dermatol.<\/i> 2024;23(4):255\u2013261.\n<\/li>\n<li>\n\u00d6hrlund \u00c5, Winl\u00f6f P, Brom\u00e9e T, et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance. <i>J Drugs Dermatol.<\/i> 2024;23(1):1332\u20131336.\n<\/li>\n<li>\nBelmontesi M, De Angelis F, Di Gregorio C, et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus. <i>J Drugs Dermatol.<\/i> 2018;17(1):83\u201388.\n<\/li>\n<li>\nEdsman K, Nord LI, \u00d6hrlund \u00c5, et al. Gel Properties of Hyaluronic Acid Dermal Fillers. <i>Dermatol Surg<\/i>. 2012;38:1170\u20131179.\n<\/li>\n<li>\nGalderma. Data on file. MA-58650. Degree of modification of HA fillers.\n<\/li>\n<li>\nData on file. MA-34483. Study Report. Galderma Laboratories, L.P., 2021.\n<\/li>\n<li>\nDi Gregorio C, Avelar L, Lam S, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.\n<\/li>\n<li>\nNikolis A, Enright KM, Lazarova D, et al. The role of clinical examination in midface volume correction using hyaluronic acid fillers: should patients be stratified by skin thickness? <i>Aesthet Surg J Open Forum<\/i>. 2020; 2(1):1\u201312.\n<\/li>\n<li>\nGalderma. Data on file. Subject satisfaction (GAIS) \u2013 NASHA and OBT Fillers. 2021.\n<\/li>\n<li>\nKablik J, Monheit GD, Yu LP, et al. Comparative physical properties of HA dermal fillers. <i>Dermatol Surg.<\/i> 2009; 35, 302\u2013312.\n<\/li>\n<li>\nBrom\u00e9e T, \u00d6hrlund \u00c5, Winl\u00f6f P, et al. A new hyaluronic acid injectable, HASHA, sets new G-prime standards. Abstract presented at AMWC 2025; Mar 27-29, 2025; Monaco.\n<\/li>\n<li>\nNarins RS, Brandt FS, Dayan SH, et al. Persistence of nasolabial fold correction with a HA dermal filler with retreatment: results of an 18-month extension study. <i>Dermatol Surg.<\/i> 2011;37: 644-650.\n<\/li>\n<li>\nTalarico S, Meski AP, Buratini L. et al. High patient satisfaction of a HA filler producing enduring full-facial volume restoration: an 18-month open multicenter study. <i>Dermatol Surg.<\/i> 2015;41: 1361\u20131369.\n<\/li>\n<li>\nSolish N, Bertucci V, Percec I, et al. Dynamics of HA fillers formulated to maintain natural facial expression. <i>J Cosmet Dermatol.<\/i> 2019;18(3): 738-746.\n<\/li>\n<li>\nPhilipp\u2010Dormston WG, Schuster B, and Podda M. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. <i>J Cosmet Dermatol.<\/i> 2020;19(7): 1600-1606.\n<\/li>\n<\/ol>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>For further information:<\/b>\n<\/p>\n<p>\nChristian Marcoux, M.Sc.<br \/>\n<br \/>Chief Communications Officer<br \/>\n<br \/><a target=\"_blank\" href=\"mailto:christian&#46;marcoux&#64;&#103;&#97;&#108;&#100;&#101;&#114;&#109;&#97;&#46;&#99;&#111;&#109;\" rel=\"nofollow\" shape=\"rect\">chr&#105;&#115;&#116;&#x69;&#x61;&#x6e;&#x2e;&#x6d;&#x61;rco&#117;&#120;&#64;&#103;&#x61;&#x6c;&#x64;&#x65;&#x72;&#x6d;a&#46;c&#111;&#109;<\/a><br \/>+41 76 315 26 50\n<\/p>\n<p>\nRichard Harbinson<br \/>\n<br \/>Corporate Communications Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x72;&#x69;&#x63;&#x68;&#x61;&#x72;&#x64;&#x2e;&#x68;&#x61;&#x72;&#x62;&#x69;&#x6e;&#x73;&#x6f;&#x6e;&#x40;&#x67;&#x61;&#x6c;&#x64;&#x65;&#x72;&#x6d;&#x61;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">r&#105;&#x63;&#x68;a&#114;&#x64;&#x2e;h&#97;&#x72;&#x62;i&#110;&#x73;&#x6f;n&#64;&#x67;&#x61;l&#100;&#101;&#x72;&#x6d;a&#46;&#x63;&#x6f;m<\/a><br \/>+41 76 210 60 62\n<\/p>\n<p>\nC\u00e9line Buguet<br \/>\n<br \/>Franchises and R&amp;D Communications Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;:&#x63;e&#108;&#x69;&#110;&#x65;&#46;&#x62;u&#x67;u&#101;&#x74;&#64;&#x67;&#97;&#x6c;&#100;&#x65;r&#x6d;a&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x63;e&#x6c;&#105;n&#x65;&#46;&#x62;&#117;g&#x75;&#101;&#x74;&#64;g&#x61;&#108;&#x64;&#x65;r&#x6d;&#97;&#46;&#x63;&#111;&#x6d;<\/a><br \/>+41 76 249 90 87\n<\/p>\n<p>\nEmil Ivanov<br \/>\n<br \/>Head of Strategy, Investor Relations, and ESG<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x65;&#x6d;&#x69;&#x6c;&#x2e;&#x69;&#x76;&#x61;&#x6e;&#x6f;&#x76;&#x40;&#x67;&#x61;&#x6c;&#x64;&#x65;&#x72;&#x6d;&#x61;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x65;&#109;&#105;l&#x2e;&#x69;&#118;a&#x6e;&#x6f;&#118;&#64;g&#x61;&#108;&#100;e&#x72;&#x6d;&#97;&#46;&#x63;&#x6f;&#109;<\/a><br \/>+41 21 642 78 12\n<\/p>\n<p>\nJessica Cohen<br \/>\n<br \/>Investor Relations and Strategy Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;a&#x69;l&#x74;&#111;&#x3a;&#106;&#x65;&#115;s&#x69;c&#x61;&#46;&#x63;&#111;&#x68;&#101;&#x6e;&#64;g&#x61;l&#x64;&#101;&#x72;&#109;&#x61;&#46;c&#x6f;m\" rel=\"nofollow\" shape=\"rect\">jes&#115;&#105;&#99;&#x61;&#x2e;&#x63;&#x6f;&#x68;&#x65;n&#64;g&#97;&#108;&#100;&#101;&#x72;&#x6d;&#x61;&#x2e;&#x63;&#x6f;m<\/a><br \/>+41 21 642 76 43\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>This approval is based on results showing the safety and effectiveness of Restylane Lyft in enhancing the chin profile, with high patient satisfaction and long-lasting results1,2 Restylane Lyft is the only hyaluronic acid (HA) injectable approved to treat the midface, facial folds and wrinkles, back of hands and the chin, with consistent results observed across &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62144","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Galderma Receives U.S. FDA Approval for Restylane\u00ae Lyft\u2122 for the Enhancement of the Chin Profile - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Galderma Receives U.S. FDA Approval for Restylane\u00ae Lyft\u2122 for the Enhancement of the Chin Profile - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"This approval is based on results showing the safety and effectiveness of Restylane Lyft in enhancing the chin profile, with high patient satisfaction and long-lasting results1,2 Restylane Lyft is the only hyaluronic acid (HA) injectable approved to treat the midface, facial folds and wrinkles, back of hands and the chin, with consistent results observed across ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T06:02:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251104411888\/en\/2632627\/22\/GALDERMA_LOGO_BLACK_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Galderma Receives U.S. FDA Approval for Restylane\u00ae Lyft\u2122 for the Enhancement of the Chin Profile\",\"datePublished\":\"2025-11-05T06:02:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\\\/\"},\"wordCount\":1601,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251104411888\\\/en\\\/2632627\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\\\/\",\"name\":\"Galderma Receives U.S. FDA Approval for Restylane\u00ae Lyft\u2122 for the Enhancement of the Chin Profile - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251104411888\\\/en\\\/2632627\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"datePublished\":\"2025-11-05T06:02:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251104411888\\\/en\\\/2632627\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251104411888\\\/en\\\/2632627\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Galderma Receives U.S. FDA Approval for Restylane\u00ae Lyft\u2122 for the Enhancement of the Chin Profile\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Galderma Receives U.S. FDA Approval for Restylane\u00ae Lyft\u2122 for the Enhancement of the Chin Profile - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/","og_locale":"en_US","og_type":"article","og_title":"Galderma Receives U.S. FDA Approval for Restylane\u00ae Lyft\u2122 for the Enhancement of the Chin Profile - Pharma Trend","og_description":"This approval is based on results showing the safety and effectiveness of Restylane Lyft in enhancing the chin profile, with high patient satisfaction and long-lasting results1,2 Restylane Lyft is the only hyaluronic acid (HA) injectable approved to treat the midface, facial folds and wrinkles, back of hands and the chin, with consistent results observed across ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-05T06:02:47+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251104411888\/en\/2632627\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Galderma Receives U.S. FDA Approval for Restylane\u00ae Lyft\u2122 for the Enhancement of the Chin Profile","datePublished":"2025-11-05T06:02:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/"},"wordCount":1601,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251104411888\/en\/2632627\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/","url":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/","name":"Galderma Receives U.S. FDA Approval for Restylane\u00ae Lyft\u2122 for the Enhancement of the Chin Profile - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251104411888\/en\/2632627\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","datePublished":"2025-11-05T06:02:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251104411888\/en\/2632627\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251104411888\/en\/2632627\/22\/GALDERMA_LOGO_BLACK_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/galderma-receives-u-s-fda-approval-for-restylane-lyft-for-the-enhancement-of-the-chin-profile\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Galderma Receives U.S. FDA Approval for Restylane\u00ae Lyft\u2122 for the Enhancement of the Chin Profile"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62144"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62144\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}